Leadership and Board of Directors

Our dynamic leadership team offers decades of experience in the biotechnology, pharmaceuticals and health care industries and are committed to advancing cell and gene therapies to help more patients. Learn more about our leaders.
Corporate Leaders
Our Leadership Team was attracted to Andelyn because of the opportunity to help clients advance innovative cell and gene therapies. They each bring unique skills and perspectives that combined will help Andelyn achieve its vision to pioneer solutions to turn hope into reality.

Wade has more than 25 years of experience in the pharmaceutical industry. He previously served as Executive Director of Quality and Analytical Development at West-Ward Pharmaceuticals, and before that spent more than 20 years at Boehringer Ingelheim in a variety of leadership roles.

Adam has a strong background of operational finance, technical accounting, procurement, information technology, legal, and corporate leadership experience with focused expertise in helping small businesses execute on growth and capitalization strategies. He started his career with Deloitte’s Chicago assurance practice, and in 2010 joined a small company in Wisconsin where he helped oversee massive organic and inorganic growth for what would become the global CDMO, Alcami Corporation.

Laura joined Andelyn after serving as the Deputy General Counsel of the Abigail Wexner Research Institute at Nationwide Children’s Hospital (NCH). Prior to joining NCH, Laura acquired expertise in intellectual property, technology and research transactions, research compliance, employment, and marketing through her service as Associate General Counsel at the University of Pittsburgh; Senior Trademark Counsel at H.J. Heinz Company; Senior Staff Attorney with the Department of Veterans Affairs; and U.S. Army JAG Officer rising to the rank of Major.

Bryan has more than 20 years of experience in various IT roles in the Pharmaceutical Industry including leadership roles across all IT practices (Information Security, Infrastructure, ERP, Quality & Mfg Systems). He started his career at Merck & Co, spent over a year working for Merck in Australia before moving back to the US and consulting for a boutique consulting firm. He has also had IT leadership roles at Boehringer Ingelheim and Hikma.

Sarah has a broad range of experience across HR functions including recruiting, coaching, performance management, and project management and has a proven track record of developing HR plans aligned with business requirements. She came to Andelyn from Honda of America, Mfg, where she focused on HR business plans and strategy as well as leading the compensation, succession planning, performance management and HR analytics teams.

Board of Directors
Our Board of Directors are business and community leaders with a passion to improve medicine and make a difference in the lives of patients.

Alex Fischer is the President and CEO of the Columbus Partnership, a civic organization of Columbus, Ohio’s, top business leaders formed in 2002 to improve the economic and cultural base of Central Ohio. The Partnership is helping to lead the One Columbus economic development effort, which is a collaboration of regional economic development organizations, and is involved with education reform efforts with Columbus City Schools. The Partnership’s members include 15 Fortune 1000 CEOs, as well as the leaders of the nation’s largest university and world’s largest research and development organization. Fischer also currently serves as Chairman of Nationwide Children’s Hospital.

Robert Hodge is an independent consultant to the Gene Therapy and Biopharmaceutic industry focused on advancing therapies into the clinic and preparing for commercialization. Previously Vice President of Technical Development at AveXis/Novartis Gene Therapies and led the process and product development of Zolgensma from phase 2 to commercialization in the US, EU, and Japan. Prior to joining AveXis, held increasing leadership roles in manufacturing, process development, and product development at Pfizer/Hospira, Kythera Biopharmaceuticals, and Amgen

C. Robert Kidder currently serves on the boards of Advanced Drainage Systems, Inc.; Microvi Biotech; Wildcat Discovery; Cohn Robbins Holding Corp.; and Andelyn Biosciences. In addition, he serves on the Boards of Trustees of Nationwide Children’s Hospital and the Wexner Center Foundation. Mr. Kidder is a former board member of Morgan Stanley, Merck, and Chrysler. He co-founded 3Stone Advisors LLC in 2006, a private equity business focused on water investment. He was Chairman and Chief Executive Officer of Borden, Inc. from January 1995 through 2004 and Duracell for the prior ten years. Both Borden and Duracell were KKR-led leveraged buyouts.

Chris leads a team comprised of scientific leaders in biological sciences, including Aldevron and Integrated DNA Technologies. He was elected to the Andelyn Biosciences Board in 2022. Chris joined Danaher in 2007 and is a member of the Danaher Leadership Team. Prior to Genomic Medicines, Chris was responsible for the overall operational results and strategic direction for the Danaher Diagnostics businesses, including Beckman Coulter, Cepheid, Leica Biosystems, and Radiometer. Prior to Danaher, he worked for The Boston Consulting Group.

Tim Robinson is the chief executive officer of Nationwide Children’s Hospital. Mr. Robinson first joined Nationwide Children’s in 1995, and his innovative approach to navigating complex economic, regulatory and business challenges has helped the hospital transform from an important regional children’s health care system into a preeminent academic medical center. Nationwide Children’s now appears annually on the U.S. News & World Report list of top ten children’s hospitals, and it is one of the National Institutes of Health’s top funded freestanding pediatric research facilities. Mr. Robinson has also championed research and related technology commercialization efforts. A total of 14 companies have now been created based on Nationwide Children’s medical and scientific discoveries, including Andelyn Biosciences.

Jeff Szekeres is currently Vice President, Corporate Development for Danaher Corporation (DHR) where he is responsible for leading corporate development efforts (including acquisition, divestitures, minority investments and strategic partnerships) for operating companies in Danaher’s Life Sciences and Diagnostics segment (~$13B 2020 revenues). Notable deals since joining Danaher include ~$45B in transactions. Prior to joining Danaher in September 2012, Jeff was Vice President, Head of Mergers & Acquisitions at Life Technologies (LIFE), a $3.8B global provider of life science and diagnostic products and services to research, medical, and applied markets.

Dr. Michael Triplett is co-founder, President, and CEO of Armatus Bio, Inc., a multi-asset gene and cell therapy company based in Columbus, Ohio developing next generation therapies for neuromuscular diseases, neurodegenerative diseases, and cancer. Dr. Triplett is co-founder and co-Chairman of Clarametyx Biosciences, Inc., an early-stage infectious disease company pursuing paradigm shifting therapeutics and vaccines for the treatment and prevention of bacterial biofilm mediated diseases, after serving as founding President and CEO. Dr. Triplett co-founded and served as President and CEO of Myonexus Therapeutics, a clinical stage gene therapy company developing first-ever treatments for limb-girdle muscular dystrophies acquired by Sarepta Therapeutics for >$225 million in April 2019.